The WACC of Allied Corp (ALID) is 6.4%.
Range | Selected | |
Cost of equity | 5.3% - 7.7% | 6.5% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 7.0% - 10.4% | 8.7% |
WACC | 5.2% - 7.6% | 6.4% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 0.31 | 0.5 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 5.3% | 7.7% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 3.3 | 3.3 |
Cost of debt | 7.0% | 10.4% |
After-tax WACC | 5.2% | 7.6% |
Selected WACC | 6.4% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
ALID | Allied Corp | 3.3 | -0.29 | -0.08 |
ASP.TO | Acerus Pharmaceuticals Corporation | 11.86 | 1.14 | 0.12 |
BAMM.CN | Body and Mind Inc | 4.09 | 0.18 | 0.05 |
COOL.CN | Core One Labs Inc | 0.04 | 0.14 | 0.13 |
CURR | Cure Pharmaceutical Holding Corp | 0.01 | -1.24 | -1.24 |
EBM.V | Eastwood Bio-Medical Canada Inc | 0 | -1.2 | -1.2 |
EVOK | Evoke Pharma Inc | 1.07 | 1.82 | 1.02 |
FLWR.V | Flowr Corp | 2.08 | 0.52 | 0.21 |
FONE.CN | Flower One Holdings Inc | 54.24 | 1.84 | 0.05 |
ROMJ.V | Rubicon Organics Inc | 0.39 | -0.94 | -0.73 |
Low | High | |
Unlevered beta | -0.01 | 0.07 |
Relevered beta | -0.03 | 0.25 |
Adjusted relevered beta | 0.31 | 0.5 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALID:
cost_of_equity (6.50%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.31) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.